Published • loading... • Updated
TranspireBio Announces Successful Completion of a Pivotal Phase 1 Study with its Proprietary Springboard™ Soft Mist Inhaler Platform
Summary by WFMZ
1 Articles
1 Articles
TranspireBio Announces Successful Completion of a Pivotal Phase 1 Study with its Proprietary Springboard™ Soft Mist Inhaler Platform
SUNRISE, Fla., Oct. 6, 2026 /PRNewswire/ -- TranspireBio Holdings Inc., an integrated U.S.-based clinical-stage, biopharmaceutical company advancing inhaled therapeutics for respiratory and systemic diseases, today announced the successful completion of a pivotal Phase 1 pharmacokinetic (PK) clinical study evaluating the…
·Pennsylvania, United States
Read Full ArticleCoverage Details
Total News Sources1
Leaning Left0Leaning Right0Center1Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
